OTCMKTS:GNBT - Generex Biotechnology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.65 -0.32 (-10.77 %) (As of 01/18/2019 04:00 PM ET)Previous Close$2.65Today's Range$2.31 - $2.8452-Week Range$0.0838 - $3.10Volume553,885 shsAverage Volume296,827 shsMarket Capitalization$104.17 millionP/E RatioN/ADividend YieldN/ABeta-4.51 ProfileDiscussionChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices. The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida. Receive GNBT News and Ratings via Email Sign-up to receive the latest news and ratings for GNBT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GNBT Previous Symbol CUSIPN/A Webwww.generex.com Phone416-364-2551Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$700,000.00 Price / Sales132.80 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-1.37Profitability EPS (Most Recent Fiscal Year)N/A Net Income$36.33 million Net MarginsN/A Return on EquityN/A Return on Assets-33.95%Miscellaneous Employees12 Outstanding Shares35,080,000Market Cap$104.17 million OptionableNot Optionable Generex Biotechnology (OTCMKTS:GNBT) Frequently Asked Questions What is Generex Biotechnology's stock symbol? Generex Biotechnology trades on the OTCMKTS under the ticker symbol "GNBT." How were Generex Biotechnology's earnings last quarter? Generex Biotechnology Co. (OTCMKTS:GNBT) issued its quarterly earnings results on Friday, October, 26th. The company reported ($0.30) earnings per share (EPS) for the quarter. View Generex Biotechnology's Earnings History. When is Generex Biotechnology's next earnings date? Generex Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Generex Biotechnology. Has Generex Biotechnology been receiving favorable news coverage? News headlines about GNBT stock have trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Generex Biotechnology earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days. Who are some of Generex Biotechnology's key competitors? Some companies that are related to Generex Biotechnology include ArQule (ARQL), Progenics Pharmaceuticals (PGNX), American Brivision (Holding) (ABVC), Kezar Life Sciences (KZR), Synthorx (THOR), Tyme Technologies (TYME), Cytokinetics (CYTK), Evelo Biosciences (EVLO), Five Prime Therapeutics (FPRX), Sinovac Biotech (SVA), TG Therapeutics (TGTX), Kindred Biosciences (KIN), Akebia Therapeutics (AKBA), Xeris Pharmaceuticals (XERS) and ZIOPHARM Oncology (ZIOP). Who are Generex Biotechnology's key executives? Generex Biotechnology's management team includes the folowing people: Mr. Joseph Moscato, CEO, Pres & Director (Age 55)Mr. Mark Corrao, CFO & Treasurer (Age 61)Mr. Andrew Ro, Chief Investment Officer, Sr. VP of Investments & Director (Age 48)Mr. Richard D. Purcell, Sr. VP of Research & Drug Devel. (Age 58)Mr. Terry R. Thompson, Chief Operating Officer (Age 61) How do I buy shares of Generex Biotechnology? Shares of GNBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Generex Biotechnology's stock price today? One share of GNBT stock can currently be purchased for approximately $2.65. How big of a company is Generex Biotechnology? Generex Biotechnology has a market capitalization of $104.17 million and generates $700,000.00 in revenue each year. Generex Biotechnology employs 12 workers across the globe. What is Generex Biotechnology's official website? The official website for Generex Biotechnology is http://www.generex.com. How can I contact Generex Biotechnology? Generex Biotechnology's mailing address is 10102 USA TODAY WAY, MIRAMAR FL, 33025. The company can be reached via phone at 416-364-2551 or via email at [email protected] MarketBeat Community Rating for Generex Biotechnology (OTCMKTS GNBT)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 58 (Vote Outperform)Underperform Votes: 45 (Vote Underperform)Total Votes: 103MarketBeat's community ratings are surveys of what our community members think about Generex Biotechnology and other stocks. Vote "Outperform" if you believe GNBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNBT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: How Do Front-End Loads Impact an Investment?